Mostrando 2 resultados de: 2
Identifying the Optimal Number of Neoadjuvant Chemotherapy Cycles in Patients with Muscle Invasive Bladder Cancer
ArticleAbstract: Purpose:We investigated the pathological response rates and survival associated with 3 vs 4 cycles oPalabras claves:drug administration schedule, neoadjuvant therapy, Survival, urinary bladder neoplasmsAutores:Barocas D.A., Bivalacqua T.J., Black P.C., Cookson M.S., Dall'Era M.A., Daneshmand S., Di Trapani E., Diego M. Carrión, Dinney C.P., D’Andrea D., Grivas P.D., Holzbeierlein J.M., Kassouf W., Lotan Y., McGrath J.S., Montgomery J.S., North S., Shariat S.F., Soria F., Spiess P.E., Sridhar S.S., Stephenson A.J., Thorpe A.C., van Rhijn B.W.G., Wright J.L., Zargar H.Fuentes:scopusXA gain-of-function mutation in DHT synthesis in castration-resistant prostate cancer
ArticleAbstract: Growth of prostate cancer cells is dependent upon androgen stimulation of the androgen receptor (AR)Palabras claves:Autores:Chang K.H., Guo X., Kapur P., Kuri B., Li R., Liu J., Lotan Y., Mirzaei H., Nelson P.S., Richard J. Auchus, Roehrborn C.G., Sharifi N., Vessella R.Fuentes:scopus